Mr. Reum has 40 years of senior executive leadership of both public and private companies. He has played many key management roles in the financing of enterprises up to CAD $1.3 billion dollars for one project. He has been an officer and director of several public companies assisting several of them through the “going public” phase of their growth. He has also been instrumental in bringing innovative new technologies from the development stage to market in the alternative energy, military and law enforcement sectors.
Ms. Keith has been a Chief Financial Officer for private and public companies listed on the TSX Venture and the Frankfurt exchanges. In addition, Ms. Keith held a senior accounting role for a public company listed on the New York Stock Exchange. Nicolette speaks three languages fluently and has a passing knowledge of several others which has served her well in international business. Nicolette will provide strong leadership in the areas of regulatory reporting, capital management and international financial reporting standards.
Dr. Reardon is Professor and Jud and Pat Harper Chair of Chemical and Biological Engineering and holds joint appointments in several other programs at Colorado State University, including Cell and Molecular Biology and Biomedical Engineering. His research combines sensor development, bioreactor analysis, systems biology, and applied microbiology and microbial ecology. Dr. Reardon received his B.S. degree from the University of Pennsylvania and his Ph.D. from Caltech, both in chemical engineering.
Mr. Kao is a partner of WDM Chartered Professional Accountants, a Vancouver-based firm with over 30 years experience. Mike is proficient with both personal and corporate accounting, providing client services such as business advisory, consultancy, accounting, and tax services. WDM is registered with the Canadian Public Accountability Board, (CPAB), and the U.S. Public Company Accounting Oversight Board, (PCAOB), requiring a commitment to maintain the highest standards of professional objectivity, audit quality, and technical excellence.
Dr. Loaiza is the former Sr. Manager of BASF New Business.
He is known as a natural leader who leverages systems thinking and networking
to drive business results. He has extensive chemicals, biotechnology and
commercial training with deep knowledge and a solid network in various value
chains including Biotech, Ag, and Nutrition and Food Safety. Dr. Loaiza
received his M.S. in Bioinorganic Chemistry from UCLA and his Ph.D. in
chemistry/ biochemistry from Purdue University.
Dr. Anne Lo
trained as a veterinary surgeon and worked in a number of clinical positions.
She subsequently joined management consulting firm Bain & Co in London,
before moving to a strategy role with WorldPay. Dr. Lo is now with Horizons
Ventures based in Hong Kong, where she primarily covered science and healthcare
investments. Dr. Lo received her B.Sc. and BVM&S degrees from the
University of Edinburgh and Ph.D. from the University of Cambridge.
Dr. Henry is a Professor of Chemistry with a joint appointment as Professor of Chemical and Biological Engineering. He served as Chair of the Department of Chemistry from 2014 2018. Dr. Henry has published over 180 peer reviewed publications and generated eight issued patents. current research includes projects to develop low cost capillary flow driven diagnostic assays and biosensors for infectious diseases (bacterial and viral) and disease biomarkers, and the creation of new tissue on a chip systems that integrate living ex vivo tissue into microfluidic devices.
Dr. Geiss is Associate Professor in Microbiology,
Immunology, and Pathology at Colorado State University. Since 2005, he has
studied RNA viruses including flaviviruses, alphaviruses, and coronaviruses.
Dr. Geiss has been supported by the NIH since 2006 to develop novel antiviral
targeting flavivirus RNA capping and define the mechanisms of viral RNA
capping. He has focused on development of novel biosensors for the detection of
infectious diseases, including pathogen nucleic acids, virus particles, intact
bacterial cells, and pathogen specific antibody responses in a variety of
Dr. Dandy has been with Colorado State University since
1992. Dr. Dandy’s research in diagnostics focuses on developing and
implementing microfluidic solutions for passive and active mixing strategies,
passive pumping, automated flow control in microfluidic networks, and
microparticle concentration and separation. He holds a total of five US patents
on two label-free biosensing technologies, the first employing an integrated
optical waveguide and the second an optical method based on enzymatic
conversion of target analyte. He is currently Professor and Department Head of
Chemical and Biological Engineering and has a joint appointment as Professor of
is the R&D Director at OptiEnz Sensors, responsible for research, product
development, and project management. He has been actively involved in
researching and developing optical biosensors for more than eight years,
receiving numerous awards including the National SMART Grant, NASA Space Grant,
and a National Science Foundation Small Business Innovation Research Award.
Dr. Heinze earned a B.S. degree in biology and a Ph.D. in biosystems engineering, both from the University of Arizona with honors.
Ms. Sauber began her career at GSK in a top sales role while
winning multiple awards for running a $20M+ per quarter territory while
performing an analyst role while on a rotation. After working in the healthcare
space, Keara joined a fintech specialty lender backed by Goldman Sachs as Vice
President. As an executive at a fast growth fintech company, Keara built
strategic partnerships with companies in various verticals to build proprietary
lending solutions, helping businesses achieve their financial goals. In 2017,
Keara and her team originated more than $50 million in capital needs.
Mr. Turner is the CEO of Manhattan Street Capital,
specializing in Reg A+, Reg D and US STO advisory services. Rod was a senior
executive for two IPOs to NASDAQ (Ashton Tate, Symantec). Built a VC firm and
was an angel investor in Ask Jeeves, INFN, AMRS, eASIC, Bloom Energy. High
energy strategic thinker. Engineer with skills in all areas of business. Rod is
considered an expert and innovator and sought-after speaker in the areas of Reg
A+, Reg D financings.
Mr. Cernetig is the founder of Catalytico. He has build brands for companies and projects measured in the billions of dollars. An award-winning journalist and filmmaker, Miro brings deep research and storytelling to brands and strategy, thanks to decades of travel throughout Canada, Asia, Europe and the United States. He has written for The Globe & Mail as bureau chief in Beijing, New York, Vancouver, Alberta and The Arctic. His writing has appeared in The International Herald Tribune, The Economist, and The Toronto Star, where he was Montreal bureau chief.
Mr. Peinado is a retired partner of the international law firm of Milbank, Tweed, Hadley & McCloy. He was a senior partner in the Firm's Global Securities group and Transportation and Space Finance team. He joined the firm in 1982 having received a JD from Harvard Law School and an MBA Harvard Business School. He has been a member of the board of the UJC since 1995.and is also a trustee of the New Jersey Chapter of The Nature Conservancy, a leading conservation and environmentally focused NGO; a director of iCivics, the largest provider of on line civic education in the US; and a director of the Alleluia Fund, the grants making arm of the Episcopal Diocese of Newark, N.J.
Mr. Reum has 40 years of senior executive leadership of both public and private companies. He has played a key role in management of the financing of many enterprises up to CAD $1.3 billion dollars for one project. He has been an officer and director of several public companies assisting several of them through the “going public” phase of their growth. He has also been instrumental in bringing innovative new technologies from the development stage to market in the alternative energy, military and law enforcement sectors.
Ms. Tsai is known for her unique skills in working with executives from companies that desire strategic advice and hands on experience in partnering, investment and brand building in the US, Europe, South America, and Asia. Currently as CEO of Tana Systems, a global software and IT company based in the US and India. Tsai leads a team of 50 engineers in the US and 500 engineers in India. She is also the CEO of Healthquest, a global biotechnology and medical technologies advisory.
Mr. Smalley has nearly 30 years’ experience practicing corporate and securities law, providing legal services for financing private and public companies. Mr. Smalley has been and continues to be a director of several capital pool companies listed for trading on the TSX Venture Exchange. He has served as director and officer of numerous public and private companies.
Mr. Doan is a retired executive who was a director/founder and Vice President of Extreme CCTV (1999 2008), a company that he helped take public on the Toronto Stock Exchange and was part of the Directors committee that saw the takeover of the company in 2007. His focus had been on developing sales channels in North America and Europe.
Mr. Cheung has more than 20 years of experience in global investment banking at JPMorgan, Lehman Brothers and Credit Suisse, advising on equities and derivatives to institutions, hedge funds and sovereign wealth funds. He is experienced in setting up new businesses, including a trading division at a U.S. bank, and has served as board member of several startups. He holds a B.Sc. in Economics from University College London and a Master’s degree in Property Valuation & Law from London Cass Business School.
If looking for more information about possible investment opportunities in Edoceo Devices, please see here...Investment Info